Trials / Completed
CompletedNCT02204644
The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML
Randomized, Multi-center, Open-label Phase III Study of the Efficacy and Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A study to observe the efficacy and the safety of Flumatinib vs Imatinib as first line treatment in patients with newly diagnosed chronic phase chronic myelogenous leukemia. Randomized,Open Label,Control
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flumatinib 600mg qd | |
| DRUG | Imatinib 400mg qd |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2017-06-01
- Completion
- 2017-12-01
- First posted
- 2014-07-30
- Last updated
- 2018-02-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02204644. Inclusion in this directory is not an endorsement.